Dopavision GmbH

Based in Germany, Dopavision GmbH is a medical technology company focused on developing innovative solutions for managing myopia in children and adolescents through digital therapy. Dopavision GmbH specializes in addressing the progression of myopia using advanced digital therapies. Founded in 2017 and headquartered in Berlin, Germany, the company has engaged in 2 investment deals, with its most recent deal occurring on April 28, 2021. The company raised EUR 12 million in a Series A funding round led by Novartis International AG, with contributions from Ababax Health GmbH, Boehringer Ingelheim Venture, Seventure Partners, and Wings Capital.

Mark Wuttke serves as the CEO, leading the company's innovative approach to eye health. Dopavision’s core offering is MyopiaX®, an innovative digital therapy designed to address the progression of myopia (nearsightedness) in children and adolescents. MyopiaX® combines selective ocular light stimulation with interactive virtual reality experiences to engage young users while delivering therapeutic benefits. By utilizing consumer electronics, MyopiaX® targets specific photosensitive cells in the retina through carefully designed sessions that last several minutes, allowing for seamless integration into daily routines.

This non-invasive approach aims to improve eye health outcomes for millions of children globally, with ongoing clinical trials supporting its efficacy and safety. The primary end users are children experiencing myopia, while parents and guardians are integral to the treatment process, overseeing usage to ensure compliance. Geographically, MyopiaX® is positioned for markets with a high prevalence of myopia, including regions in Europe, Asia, and North America, reflecting the company’s commitment to addressing this pressing public health challenge. Dopavision's revenue structure revolves around the MyopiaX® product, which operates on a subscription-based model, ensuring ongoing treatment access for families.

Customers, primarily parents of children diagnosed with myopia, engage with the product through direct-to-consumer transactions, facilitated via a user-friendly app that simplifies the therapeutic process. Each subscription may include features such as progress monitoring and access to various interactive games designed to enhance treatment adherence. This model creates a consistent revenue stream and encourages user engagement through regular updates and educational content. The company’s innovative approach positions MyopiaX® as a flagship product in the growing market for digital health solutions targeted at visual impairment, further solidifying its commitment to improving eye health in children.

In April 2021, Dopavision GmbH raised EUR 12 million in Series A funding to advance the clinical development of MyopiaX®. The company plans to utilize these funds for additional product development activities and to recruit talent for its development team. Dopavision aims to expand its market presence in Europe, Asia, and North America, targeting regions with high myopia prevalence, and is focused on launching new features for MyopiaX® that enhance user experience and treatment efficacy.